Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits
- Design
- Meta-analysis
- Drugs
- Dulaglutide, Tirzepatide
- Assessment
- Not yet reviewed by a person · added Oct 18, 2026
This study was added automatically and has not been reviewed. Until it is, the collection publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.
01Source
The source, as retrieved
Abstract
[OBJECTIVES] To comprehensively synthesize and quantify the multiorgan effects of tirzepatide across 10 health domains beyond its primary indications for type 2 diabetes and obesity. [METHODS] We searched PubMed, Embase, and CENTRAL through January 2026 for randomized controlled trials of tirzepatide (≥24 weeks) reporting on cardiovascular, heart failure, renal, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, blood pressure, lipids, quality of life, body composition, or inflammatory outcomes. Data from 17 randomized controlled trials (N = 25 847) were pooled using random-effects models, with risk of bias assessed via Cochrane Risk of Bias 2 and evidence certainty rated using Grading of Recommendations, Assessment, Development, and Evaluations. [RESULTS] Tirzepatide demonstrated noninferiority to dulaglutide for major adverse cardiovascular events (HR 0.92, 95% CI 0.83-1.02). In heart failure outcomes in patients with preserved ejection fraction patients, it reduced cardiovascular death or heart failure events by 38% (HR 0.62, 95% CI 0.41-0.95). Additional benefits included: MASH resolution in 62% of patients (RR 5.33), clinically significant apnea-hypopnea index reduction (21.9 events/hour), systolic blood pressure reduction (5.8 mmHg), triglyceride reduction (19.6%), estimated glomerular filtration rate preservation (+1.5 mL/min/year), and high-sensitivity C-reactive protein reduction (32.9%). [CONCLUSIONS] Tirzepatide provides clinically significant, multiorgan benefits across heart failure, MASH, sleep apnea, blood pressure, lipids, and inflammation. Supported by moderate-to-high certainty evidence, it emerges as a comprehensive cardiometabolic protective agent. However, findings for domains like heart failure and MASH resolution rely on few trials, necessitating cautious interpretation regarding generalizability.